Independent Financial Information Made Easy
The development of Artificial Intelligence (AI) is modifying the way investments are evaluated. We programmed an artificial intelligence (A.I.) to summarize the whole internet. Whether you’re trying to make money investing online, making financial decisions or just getting informed about Wall Street, this page is a way to get informed without reading hundred of pages. Our stock market summary graphs are produced using machine learning, an unbiased view to capture what internet is saying. Usually, the AI reads several hundred pages and summarize it to a short text and several charts.
Viridian Therapeutics shares rise 8.7% after selecting go-forward candidate for thyroid eye disease treatment. Company had revenue of $347.00K in the twelve months ending September 30, 2023. Viridian Therapeutics has a 1-year low of $10.93 and a 1 year high of $39.00. The company last issued its earnings results on Monday, November 13th. Viridian Therapeutics ( NASDAQ:VRDN – Get Free Report ) last announced its earnings results on Monday, November 13th. Viridian had a negative net margin of 62,437.76% and a negative return on equity of 108.58%. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Today, the firm is suggested as a BUY with a 0.41-star rating and a target price of $30.00.
Open: 22.1 Close: 20.43 Change: -1.67
Read more →